CLINICAL_TRIALS
trial_result
· 2017-04-13
Clinical Trial Update: Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer [Phase 2]
Summary
A Phase II trial of VS-6063 (defactinib) in KRAS-mutant non-small cell lung cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Verastem, Inc. | Conditions: Non Small Cell Lung Cancer, Lung Cancer | Phase 2 | Status: COMPLETED